Truvada

HIV-1 Treatment

Truvada is used in combination with other antiretroviral medications to treat human immunodeficiency virus type 1 (HIV-1) infection. It is prescribed for adults and children who weigh at least 17 kilograms (about 37 pounds). While it helps manage the virus and supports the immune system, it is not a cure for HIV or AIDS.

Pre-Exposure Prophylaxis (PrEP)

This medication is also used for pre-exposure prophylaxis (PrEP) to reduce the risk of getting HIV-1 through sexual activity. For this purpose, it is used by adults and adolescents weighing at least 35 kilograms (about 77 pounds) who are at high risk of infection. When used for PrEP, the following conditions apply:

• HIV-Negative Status: You must have a confirmed negative HIV test immediately before starting Truvada for PrEP.
• Regular Testing: Frequent HIV testing is required while taking the medication to ensure you remain HIV-negative.
• Comprehensive Prevention: It is intended to be used as part of a complete prevention strategy that includes safe sex practices, such as consistent condom use.

Mechanism of Action

Truvada is a combination of two medications: emtricitabine and tenofovir disoproxil fumarate. Both belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs).

These medications work by interfering with an enzyme called reverse transcriptase. HIV uses this enzyme to copy its genetic material, which allows the virus to multiply and infect new cells. By blocking this process, Truvada helps to:

• Reduce viral load: In people already living with HIV, it lowers the amount of the virus in the blood to help manage the condition.
• Support the immune system: By slowing the spread of the virus, it allows the body's immune system, specifically CD4 cells, to stay healthier.
• Prevent infection: When used as pre-exposure prophylaxis (PrEP), the medication stays in the bloodstream and tissues to help stop HIV from establishing a permanent infection if a person is exposed to the virus.

It is important to note that while Truvada helps control or prevent HIV infection, it is not a cure for HIV or AIDS.

Common Side Effects

Many people experience mild side effects when they first start taking this medication. These symptoms often go away over time and may include:

• Nausea or vomiting
• Diarrhea
• Headache
• Dizziness
• Fatigue or weakness
• Trouble sleeping or strange dreams
• Weight loss
• Skin rash or darkening of the skin on the palms or soles of the feet

Serious Side Effects

Some side effects can be severe and require prompt medical evaluation. Seek medical help if you notice any of the following:

• Kidney problems: Symptoms may include changes in urination, swelling in the legs or feet, or feeling unusually tired.
• Bone thinning: This medication can cause a decrease in bone mineral density, which may lead to bone pain or an increased risk of broken bones.
• Lactic acidosis: This is a serious condition where too much acid builds up in the blood. Signs include muscle pain, stomach pain with nausea, cold limbs, dizziness, or a fast heartbeat.
• Liver issues: Watch for yellowing of the skin or eyes, dark urine, or pain in the upper stomach area.
• Immune system changes: The immune system may sometimes react strongly to past infections shortly after starting the medication.

Boxed Warnings

Truvada carries boxed warnings for several serious risks. Severe, acute flare-ups of hepatitis B (HBV) have occurred in individuals who stop taking this medication. Liver function monitoring is typically required for several months after discontinuation. Additionally, when used for pre-exposure prophylaxis (PrEP), Truvada must only be used by those confirmed to be HIV-negative. Using the drug while having an undiagnosed HIV infection can cause the virus to develop resistance to treatment.

Kidney and Bone Health

This medication may cause new or worsening kidney impairment, including kidney failure. Healthcare providers often perform blood and urine tests to monitor kidney function. There is also a risk of decreased bone mineral density, which can lead to bone thinning or an increased risk of fractures.

Lactic Acidosis and Liver Issues

A rare but life-threatening condition called lactic acidosis, where too much acid builds up in the blood, has been reported. Severe liver enlargement and fatty liver (steatosis) are also potential risks. These conditions require immediate medical evaluation.

HIV Testing Requirements

For individuals using Truvada for PrEP, regular HIV testing is necessary at least every three months. It is critical to ensure a negative HIV status before starting and while continuing the medication to avoid the development of drug-resistant HIV.

Immune System Reactions

In some cases, the immune system may become overactive after starting HIV treatment, potentially causing the body to react to previous or hidden infections. This condition is referred to as immune reconstitution syndrome.

Pregnancy

Truvada is used during pregnancy both to treat HIV and as pre-exposure prophylaxis (PrEP) to prevent HIV infection. Current research has not shown a clear link between the use of this medication and an increased risk of major birth defects. However, because data is still being collected, Truvada should only be used during pregnancy if it is clearly needed and discussed with a healthcare provider.

A pregnancy registry exists to monitor the health of individuals and their infants who are exposed to antiretroviral medications. Enrolling in such a registry helps healthcare professionals better understand the long-term safety of Truvada during pregnancy.

Breastfeeding

The active ingredients in Truvada pass into breast milk. The recommendations for breastfeeding vary based on the reason for taking the medication:

• HIV Treatment: For individuals who have HIV, health authorities generally recommend against breastfeeding. This is to prevent the risk of transmitting the virus to the infant through breast milk, even if the individual's viral load is undetectable.
• HIV Prevention (PrEP): For individuals without HIV who are taking Truvada for prevention, the effects of the medication on a nursing infant are not fully known. The decision to breastfeed while on PrEP involves weighing the benefit of preventing HIV infection against the potential risks to the baby.

It is important to consult with a healthcare professional to determine the safest feeding plan for your specific situation.

Available Forms

Truvada is provided as a film-coated tablet for oral administration. It is a fixed-dose combination medication, which means it contains more than one active ingredient in each pill.

The tablets are capsule-shaped and are available in different colors and with different markings depending on the specific formulation prescribed.

FDA Approval and Indications

Truvada, a combination of emtricitabine and tenofovir disoproxil fumarate, is approved by the U.S. Food and Drug Administration (FDA) for two primary indications. It is used in combination with other antiretroviral agents to treat HIV-1 infection in adults and pediatric patients weighing at least 17 kg. It is also approved for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing at least 35 kg.

Boxed Warnings

The FDA requires a boxed warning for Truvada, which is the most serious type of warning for prescription medications. These warnings include:

• Risk of Drug Resistance: When used for PrEP, Truvada must only be prescribed to individuals confirmed to be HIV-negative immediately prior to starting the drug and at least every three months while taking it. Using Truvada for PrEP in someone with an undetected HIV-1 infection can lead to the development of drug-resistant viral strains, making the infection harder to treat.
• Hepatitis B Exacerbation: Severe, acute flare-ups of hepatitis B virus (HBV) have been reported in patients who have both HIV-1 and HBV and then stop taking Truvada. Healthcare providers are advised to monitor liver function closely for several months in patients with HBV who discontinue the medication.

Regulatory Requirements and Monitoring

To ensure safe use for PrEP, the FDA emphasizes strict adherence to screening protocols. This includes confirming a negative HIV-1 status before initiation and regular testing during use. While the FDA previously managed these risks through a formal Risk Evaluation and Mitigation Strategy (REMS), the current focus is on provider education and the distribution of safety materials to ensure patients understand the importance of regular testing and adherence.

Generic Options

A generic version of Truvada, containing emtricitabine and tenofovir disoproxil fumarate, is available. Generic medications typically cost less than brand-name versions while providing the same therapeutic benefits.

Insurance and PrEP Coverage

Most insurance plans cover Truvada for the treatment of HIV. When used for PrEP (pre-exposure prophylaxis), many health plans are required to cover the medication with no out-of-pocket costs for the patient, though specific requirements may vary by plan.

Financial Assistance Programs

Several options may be available to help manage the cost of Truvada:

• Co-pay Coupons: The manufacturer may offer savings cards for patients with commercial insurance to reduce monthly out-of-pocket expenses.
• Patient Assistance Programs: Programs exist to provide the medication at no cost to eligible individuals who do not have insurance coverage.
• Government Programs: Programs such as Medicare Part D or the Ryan White HIV/AIDS Program may provide coverage or financial support for those who qualify.

Patients are encouraged to check with their insurance provider and pharmacist to determine their specific costs and eligibility for assistance.